04:26 PM EST, 01/09/2025 (MT Newswires) -- Aptose Biosciences ( APTO ) dosed the first set of patients in the phase 1/2 study of tuspetinib in combination with venetoclax and azacitidine in patients newly diagnosed with acute myeloid leukemia.

Patient enrollment is expected to be 18 to 24 in mid- to late 2025, the company said Thursday in a statement.